Followers | 97 |
Posts | 128742 |
Boards Moderated | 1 |
Alias Born | 07/24/2016 |
Thursday, October 28, 2021 7:30:33 AM
Q BioMed (QBIO) aims to accelerate the monetization of biomedical technologies through rapid
innovation and collaborative partnerships with industry leading researchers. Q BioMed launched its
FDA approved, non-opioid drug Strontium89 (strontium chloride Sr-89 Injection, USP), which
relieves pain from metastatic cancer in the bone, in the U.S. in February 2020. Strontium89 is
Medicare/payor reimbursed in the U.S. and is available outside the U.S. to a potential global
population of 10 million people through a Named Patient Program. Q BioMed’s clinical pipeline in
oncology, vascular disease, and rare orphan diseases addresses unmet medical needs in large
markets and is expected to produce substantial revenues for the Company and value inflection
points for investors for years to come.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM